Diana P. Friedman is joining Novalar Pharmaceutical as VP/marketing and will lead efforts for the company's dental specialty pharmaceutical products as well as the anticipated fall 2008 launch of a
local anesthetic reversal agent for use following routine dental procedures.
Friedman joins Novalar from Philips Oral Healthcare.
San Diego, Calif.-based Novalar is a dental specialty
pharmaceutical company dedicated to developing and commercializing novel oral health care solutions. Its initial product offering, NV-101, is being evaluated as a local anesthetic reversal agent and
was developed to rapidly reverse the lingering and debilitating lip and tongue numbness associated with local dental anesthesia.
--Tanya Irwin